VMware recently entered into partnerships with various healthcare organizations including Moffitt Cancer Center and VITAS Healthcare. Notably, the health centers will be leveraging the company’s robust healthcare solutions to improve cost and quality of patient care.
VMware’s continued innovations in the healthcare IT space resulted in the creation of a digital clinical workplace on a single device, Workspace ONE. This device benefits patients by not only helping them comprehend their diagnosis and alternative treatment options but also keeps the patients connected outside the four walls of the hospital by providing access to social media platforms and games.
VITAS Healthcare has deployed Workspace ONE in its daily operations. This helps healthcare providers in getting immediate access to patient information, while being away from the hospital. Since the solution can be deployed on hospital-owned or care provider’s personal devices, it benefited the company in reducing device related costs for clinical work station by 35%.
Moffitt Cancer Center uses the company’s NSX solutions to help protect patient information. Further, NSX allows the company to securely exchange research information with other universities and research centers around the world, lowering Moffitt’s legacy model expenses.
VMware, Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
VMware recently entered into partnerships with various healthcare organizations including Moffitt Cancer Center and VITAS Healthcare. Notably, the health centers will be leveraging the company’s robust healthcare solutions to improve cost and quality of patient care.
VMware’s continued innovations in the healthcare IT space resulted in the creation of a digital clinical workplace on a single device, Workspace ONE. This device benefits patients by not only helping them comprehend their diagnosis and alternative treatment options but also keeps the patients connected outside the four walls of the hospital by providing access to social media platforms and games.
VITAS Healthcare has deployed Workspace ONE in its daily operations. This helps healthcare providers in getting immediate access to patient information, while being away from the hospital. Since the solution can be deployed on hospital-owned or care provider’s personal devices, it benefited the company in reducing device related costs for clinical work station by 35%.
Moffitt Cancer Center uses the company’s NSX solutions to help protect patient information. Further, NSX allows the company to securely exchange research information with other universities and research centers around the world, lowering Moffitt’s legacy model expenses.
VMware, Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on IBM - FREE
Get the latest research report on JBL - FREE
Get the latest research report on TWLO - FREE